Effect of gastric bypass versus diet on cardiovascular risk factors

Ann Surg. 2014 Apr;259(4):694-9. doi: 10.1097/SLA.0b013e31829d6989.

Abstract

Objective: To assess the effect of Roux-en-Y gastric bypass (RYGB) on high-density lipoprotein cholesterol (HDL-C) concentration and its apolipoprotein A4 (ApoA4) content at 1 year after bariatric surgery in comparison with a hypocaloric diet. Secondary aim was to measure total cholesterol and triglycerides levels and insulin sensitivity after interventions.

Background: Very few prospective uncontrolled studies have investigated the effects of RYGB on cardiovascular risk factors. No controlled studies had as primary goal the changes in HDL-C after gastric bypass.

Methods: Forty subjects with a body mass index more than 40 or 35 kg/m or more in the presence of diabetes were enrolled. Twenty of them underwent RYGB, whereas 20 received lifestyle modification suggestions and medical therapy for obesity complications (diabetes, hypertension, and hyperlipidemia).

Results: A significant (P < 0.0001) increase in HDL-C concentrations was observed only in the surgical arm (from 41.95 ± 7.24 to 56.55 ± 9.01 mg/dL). Mean systolic and diastolic blood pressures were significantly reduced (P < 0.0001) in both groups with no between-group differences, probably in relation to the optimization of the antihypertensive treatment. Plasma concentration of ApoA4, a major HDL-C protein fraction, significantly increased 1 year after RYGB (from 496.61 ± 400.41 to 987.88 ± 637.41μg/L, P < 0.01). Circulating triglycerides concentration significantly decreased after surgery, whereas both peripheral and hepatic insulin resistance increased significantly.

Conclusions: Our study shows that HDL-C and ApoA4 significantly increase after gastric bypass and that this increase is associated with a net improvement in hepatic insulin sensitivity. Furthermore, we speculate that ApoA4, which induces satiety in animals, can eventually play a role on the appetite reduction after RYGB because there is a strict and inverse relationship between weight and ApoA4 changes. (NCT01707771).

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adult
  • Apolipoproteins A / blood*
  • Biomarkers / blood
  • Blood Pressure
  • Caloric Restriction*
  • Cholesterol / blood
  • Cholesterol, HDL / blood*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / complications
  • Exercise
  • Female
  • Follow-Up Studies
  • Gastric Bypass*
  • Humans
  • Insulin Resistance
  • Male
  • Middle Aged
  • Obesity / blood
  • Obesity / complications
  • Obesity / therapy*
  • Obesity, Morbid / blood
  • Obesity, Morbid / complications
  • Obesity, Morbid / therapy
  • Prospective Studies
  • Risk Factors
  • Treatment Outcome
  • Triglycerides / blood
  • Weight Reduction Programs

Substances

  • Apolipoproteins A
  • Biomarkers
  • Cholesterol, HDL
  • Triglycerides
  • apolipoprotein A-IV
  • Cholesterol

Associated data

  • ClinicalTrials.gov/NCT01707771